Moreover, such DNCaNPs upon administration could not only directly cause effective ICD of cancer cells and then elicit the host’s antitumor immunity, but also reduce the density of immunosuppressive Tregs inside TMEs by synergistically inhibiting IDO1 and neutralizing tumor acidity. This evidence concerns the gene IDO1 and cancer.